Navigation Links
Amicus Therapeutics Announces Second Quarter 2008 Financial Results
Date:8/7/2008

re-tax charges for changes in the fair value of warrant liability

Use of Non-GAAP Financial Measures

Amicus' "non-GAAP net loss" and "non-GAAP diluted net loss per common share" financial measures are defined as reported, or GAAP, net loss and diluted net loss per common share excluding certain items further discussed below. Amicus' management uses these non-GAAP financial measures to establish financial goals and to gain an understanding of the comparative financial performance of Amicus from year to year and quarter to quarter. Accordingly, Amicus believes investors' understanding of Amicus' financial performance is enhanced as a result of disclosing these non-GAAP financial measures. Non-GAAP net loss and diluted net loss per common share should not be viewed in isolation or as a substitute for reported, or GAAP net loss and diluted net loss per common share.

(1) Stock option expense -- Non-GAAP net loss and diluted net loss per

common share exclude the impact of the stock option expense recorded

in accordance with SFAS No. 123R. Amicus believes that excluding the

impact of expensing stock options better reflects the recurring

economic characteristics of its business.

(2) Other items -- Non-GAAP net loss and diluted net loss per common

share exclude other unusual or non-recurring items that are evaluated

on an individual basis. Amicus' evaluation of whether to exclude an

item for purposes of determining its non-GAAP financial measures

considers both the quantitative and qualitative aspects of the item,

including, among other things (i) its size and nature, (ii) whether

or not it relates to its ongoing business operations, and (iii)

whether or not Amicus expects it to occur as part of its normal

business on a regular basis. Items excluded for purposes of

determining non-GAAP net loss and
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
2. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
3. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
6. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
7. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
8. Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
9. Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
10. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
11. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...E, N.J., Nov. 25 Regado Bioscience...t of antithrombotic aptamers with active control a...esident, will be presenting at the Piper Jaffray 2...Palace Hotel in New York City. Dr. Mazzo,s presen...ecember 1 and will include an overview of the Comp...
(Date:11/25/2009)...lif., Nov. 25 Abaxis, In...nufacturing point-of-care blood analysis systems, ...chief executive officer, will present at the 21st ...nesday, December 2, 2009 at 2:00 p.m. ET. The conf...n New York City. ,, About Abaxis ,, Abaxi...
(Date:11/25/2009)...LL, N.C., Nov. 25 Cempra Pharmaceu...ndes, president and chief executive officer, will ...re Conference at 8:50 a.m. EST, December 1, 2009, .... Fernandes will provide an overview of the compan...he treatment of drug-resistant pathogens including...
Breaking Medicine Technology:Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2The American Legion Calls for Revamping and Expansion of Veterans and Military Health Care 55198 1The American Legion Calls for Revamping and Expansion of Veterans and Military Health Care 55198 2Chronic Media Multi Tasking Makes It Harder to Focus 55193 1Chronic Media Multi Tasking Makes It Harder to Focus 55193 2Chronic Media Multi Tasking Makes It Harder to Focus 55193 3Encorium Reports Second Quarter 2009 Financial Results 13673 1Encorium Reports Second Quarter 2009 Financial Results 13673 2Encorium Reports Second Quarter 2009 Financial Results 13673 3Encorium Reports Second Quarter 2009 Financial Results 13673 4Encorium Reports Second Quarter 2009 Financial Results 13673 5Encorium Reports Second Quarter 2009 Financial Results 13673 6Encorium Reports Second Quarter 2009 Financial Results 13673 7Encorium Reports Second Quarter 2009 Financial Results 13673 8Encorium Reports Second Quarter 2009 Financial Results 13673 9
...niversity Medical Center Only Illinois Site in Tri...s who received an,new intravenous adult stem cell ...er of adverse events, such as cardiac,arrhythmias,...nd,global function compared to those who received ...ta presented at the American College,of Cardiology...
...resentation of Comparative Data from ECLIPSE, Larg... Agents, NEW ORLEANS, March 27, 2007 /PRNewswire-F...onal drug Cleviprex(TM) (clevidipine),compared to ...trolling perioperative hypertension -- a potential..., during and/or after,surgery -- were presented fo...
Other Medicine Technology:Heart Attack Patients Treated With Novel Stem Cell Therapy,Experience Significant Improvement in Heart and Lung Function 2Heart Attack Patients Treated With Novel Stem Cell Therapy,Experience Significant Improvement in Heart and Lung Function 3Pivotal Phase III Findings With Investigational Drug Cleviprex,(Clevidipine) Demonstrate Perioperative Blood Pressure Control In,Cardiac Surgery 2Pivotal Phase III Findings With Investigational Drug Cleviprex,(Clevidipine) Demonstrate Perioperative Blood Pressure Control In,Cardiac Surgery 3Pivotal Phase III Findings With Investigational Drug Cleviprex,(Clevidipine) Demonstrate Perioperative Blood Pressure Control In,Cardiac Surgery 4Pivotal Phase III Findings With Investigational Drug Cleviprex,(Clevidipine) Demonstrate Perioperative Blood Pressure Control In,Cardiac Surgery 5
(Date:11/27/2009)..., DALLAS, Nov. 27 Co...procedure only 25 years ago, solid organ transplan...hanks to the extraordinary men and women who gathe...11. Leaders came together from medical centers aro... Baylor Regional Transplant Institute (BRTI), one ...
(Date:11/27/2009)..., ROCHESTER, N.Y., Nov. 27 /PRNewswire-USNewswi...lth care provider and fortunately every year, new ...ention. But do all vaccines boost immunity for the...onal ,booster shots, needed to keep immunity stron...e Journal of the American Academy of Pediatrics, M...
(Date:11/27/2009)..., KIBBUTZ SHAMIR, Israel, Nov. 27 /PRNewswire-Fi... SHMR ) ( "Shamir" ), a leading provider of innova...s market, announced today that its board of direct...regate amount of US$ 10 million (approximately NIS...esentative rate of exchange), or approximately US$...
(Date:11/27/2009)... and cycling plus low-emission vehicles may reduce... , FRIDAY, Nov. 27 (HealthDay News) -- Encouragin...ng cars would offer much greater public health ben..., U.K. researchers have found. , The study comp...native urban land transport scenarios for London, ...
(Date:11/27/2009)... , SEATTLE, Nov. 27 /PRNewswire/...received record-high Thanksgiving traffic numbers,...e Thanksgiving, providing a clear picture of what .... The average Thanksgiving meal in 2009 weighed in...se from last year,s feast. According to the Allrec...
Breaking Medicine News(10 mins):Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 2Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 3Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 2Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 3Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 4
...manian government officials traveled halfway aroun... (CSHL), to lend their support and extend their gr...ue transmissible and rapidly spreading cancer that...sciences is committing resources to sequence parts...
...Most Complete Submission Linking Capabilities, PH...,part of The Thomson Corporation (NYSE: TOC ; TSX...ns to the worldwide research and business,communit...ence management to its enhanced functionality set....
...ise for human protection in future , , MON... placed under the tongue might one day ward off th...ted only in mice, be more convenient, it also appe...le who are afraid of needles, but it,s clearly an ...
...e University researchers is the first to conduct a...nce of factors that contribute to DNA mutations, w...ical disorders. Led by assistant professor of bio... of microsatellites -- variable-length sequences o...
.... 28 Noting recent crises,involving the safety of...ngs of a governmental blue ribbon panel, Jim Marti...e U.S. Food & Drug Administration "itself a,threat...organize and renew the agency as the,safeguard of ...
...American Academy of,Pediatrics (AAP) is demanding ...duled for Thursday, January 31. As reported in The... argues in court that a vaccine caused a,child,s a...impression; the jury awards the mother $5.2 millio...
Other Medicine News:Health News:Cold Spring Harbor Laboratory researchers race against time to save Tasmanian devils 2Health News:Liquent Insight Publisher 3.6 Delivers Advanced Submission Capabilities 2Health News:Drop of Flu Vaccine Under Tongue Bars Infection 2Health News:Scientists explore factors contributing to DNA mutations 2Health News:Scientists explore factors contributing to DNA mutations 3Health News:Scientists explore factors contributing to DNA mutations 4Health News:Don't Overburden FDA 2Health News:American Academy of Pediatrics Calls for Cancellation of ABC's 'Eli Stone' Premiere 2
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
Medicine Products: